U.S. Health Secretary Robert F. Kennedy Jr. has named eight new members to the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), following the abrupt dismissal of all 17 prior members. The newly appointed panel includes several figures known for expressing skepticism about vaccines, particularly mRNA technology.
Among the new appointees is Robert Malone, a vocal critic of mRNA COVID-19 vaccines and an ally of Kennedy’s "Make America Healthy Again" movement. Other members include Joseph Hibbeln, Martin Kulldorff, Retsef Levi, Cody Meissner, James Pagano, Vicky Pebsworth, and Michael Ross—some of whom have ties to prior CDC or FDA vaccine panels, while others have promoted views critical of current vaccination practices.
Kennedy, who has long challenged vaccine safety despite scientific consensus, claimed the former panel had conflicts of interest, although he did not provide specific evidence. He emphasized the reshuffle was meant to “restore public trust in vaccine science.”
The new ACIP members will participate in the committee’s June 25–27 meeting, where decisions are expected on vaccine recommendations for flu shots and the 2025–26 COVID-19 boosters. The meeting agenda has yet to be released.
The move sparked market reactions: Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) shares dipped slightly, while Novavax (NASDAQ:NVAX), which produces a non-mRNA COVID-19 vaccine, saw a marginal rise.
Concerns remain about the vetting process for the new members. Some, like Pebsworth and Meissner, have served on FDA advisory committees, while others, such as Levi and Kulldorff, have made controversial statements questioning mRNA vaccine safety.
Despite FDA confirmation that mRNA vaccines are safe and effective, Kennedy’s overhaul has intensified the national debate on vaccine policy and public health strategy.


Judge Orders Return of Seized Evidence in Comey-Related Case, DOJ May Seek New Warrant
Israeli Airstrike in Gaza Targets Senior Hamas Commander Amid Ceasefire Tensions
Supporters Gather Ahead of Verdict in Jimmy Lai’s Landmark Hong Kong National Security Trial
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Zelenskiy Signals Willingness to Drop NATO Bid as Ukraine, U.S. Hold Crucial Peace Talks in Berlin
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform
International Outcry Grows Over Re-Arrest of Nobel Laureate Narges Mohammadi in Iran
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Belarus Frees 123 Political Prisoners in U.S.-Brokered Deal Over Sanctions
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Preservation Group Sues Trump Administration to Halt $300 Million White House Ballroom Project
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 



